Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOTUM | Q6P988 | 3/20 | 0.55 |
| ▸ | FFAR4 | Q5NUL3 | 2/20 | 0.50 |
| ▸ | ITGB2 | P05107 | 2/20 | 0.49 |
| ▸ | ICAM1 | P05362 | 2/20 | 0.49 |
| ▸ | ITGAL | P20701 | 2/20 | 0.49 |
| ▸ | LRRK2 | Q5S007 | 2/20 | 0.45 |
| ▸ | PDE4A | P27815 | 1/20 | 0.45 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.45 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.45 |
| ▸ | DPP4 | P27487 | 4/20 | 0.44 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.43 |
| ▸ | ABL1 | P00519 | 3/20 | 0.43 |
| ▸ | BCR | P11274 | 1/20 | 0.43 |
| ▸ | MMP12 | P39900 | 1/20 | 0.43 |
| ▸ | DGAT2 | Q96PD7 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21434043 | 0.88 | MAP4K4 (0.46) | NOTUMITGB2ICAM1ITGALSCN9A | |
| SCHEMBL21433972 | 0.86 | ITGB2 (0.54) | FFAR4ITGB2ICAM1ITGALLRRK2 | |
| SCHEMBL21434097 | 0.85 | ITGB2 (0.56) | ITGB2ICAM1ITGALLRRK2DPP4 | |
| SCHEMBL21434055 | 0.84 | EPHX2 (0.44) | FFAR4ITGB2ICAM1ITGALLRRK2 | |
| SCHEMBL21433952 | 0.81 | KIT (0.46) | DPP4ABL1BCR | |
| SCHEMBL21433969 | 0.81 | CHRM4 (0.51) | ABL1BCR | |
| SCHEMBL21433920 | 0.80 | ITGB2 (0.46) | ITGB2ICAM1ITGALSCN9AABL1 | |
| SCHEMBL21434098 | 0.80 | SMPD3 (0.51) | ITGB2ICAM1ITGALSCN9AABL1 | |
| SCHEMBL21433963 | 0.80 | ABL1 (0.46) | ITGB2ICAM1ITGALDPP4SCN9A | |
| SCHEMBL14660647 | 0.78 | NOTUM (0.57) | NOTUMITGB2ICAM1ITGAL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210340121-A1 | SUBSTITUTED PYRIDINE AND PYRIMIDINES AND THEIR USE AS GLUN2B RECEPTOR MODULATORS | JANSSEN PHARMACEUTICA NV (BE) | 2021-11-04 | — | — | US | disclosed |
| US-11008302-B2 | Substituted pyridine and pyrimidines and their use as GluN2B receptor modulators | JANSSEN PHARMACEUTICA NV (BE) | 2021-05-18 | — | — | US | disclosed |
| EP-3774732-A2 | SUBSTITUTED PYRIDINE AND PYRIMIDINES AND THEIR USE AS GLUN2B RECEPTOR MODULATORS | Janssen Pharmaceutica NV (BE) | 2021-02-17 | — | — | EP | disclosed |
| WO-2019193516-A2 | SUBSTITUTED PYRIDINE AND PYRIMIDINES AND THEIR USE AS GLUN2B RECEPTOR MODULATORS | JANSSEN PHARMACEUTICA NV (BE) | 2019-10-10 | — | — | WO | disclosed |
| US-20190308950-A1 | SUBSTITUTED PYRIDINE AND PYRIMIDINES AND THEIR USE AS GLUN2B RECEPTOR MODULATORS | JANSSEN PHARMACEUTICA NV (BE) | 2019-10-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190308950-A1 | SUBSTITUTED PYRIDINE AND PYRIMIDINES AND THEIR USE AS GLUN2B RECEPTOR MODULATORS | GRIN2B, GRIN2A, GRIN3B | NOTUM 4801/4885FFAR4 339/4885ITGB2 1763/4885 |
| US-20210340121-A1 | SUBSTITUTED PYRIDINE AND PYRIMIDINES AND THEIR USE AS GLUN2B RECEPTOR MODULATORS | GRIN2B, GRIN2A, GRIN3B | NOTUM 4801/4885FFAR4 339/4885ITGB2 1763/4885 |
| US-11008302-B2 | Substituted pyridine and pyrimidines and their use as GluN2B receptor modulators | GRIN2B, GRIN2A, GRIN3B | NOTUM 4816/4885FFAR4 519/4885ITGB2 1693/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.